CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

NCT ID: NCT00374179

Last Updated: 2009-02-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-08-31
• Study Completion Date: 2009-02-28

Brief Summary

RATIONALE: CT-322 may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.

PURPOSE: This phase I trial is studying the side effects of CT-322 in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.

Conditions

Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

CT-322

IV solution, weekly or bi-weekly

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS

• Histologically proven advanced solid malignancy or NHL for which no standard therapy exists or for which standard therapy had failed
• No known brain or leptomeningeal disease
• No prior bone marrow transplant or stem cell rescue
• No histologically confirmed squamous non-small cell lung cancer (NSCLC) with central chest tumor(s) still in place

PATIENT CHARACTERISTICS

Age:

• 18 and over

Performance status:

• ECOG performance status ≤ 2

Life expectancy:

• > 3 months

Hematopoietic:

• ANC ≥ 1500/mL
• Platelets ≥ 100,000/mL
• Hemoglobin ≥ 9.0 g/dL; and not requiring transfusion > 1 unit/month

Hepatic:

• AST and ALT ≤ 2.5 x ULN; if liver function abnormalities are due to the underlying malignancy, then AST and ALT may be ≤ 5 x the ULN
• Bilirubin ≤ 1.5 x ULN
• aPTT and PT < 1.5 x ULN

Renal:

• Creatinine ≤ 1.5 x ULN; patients with serum creatinine > 1 x ULN must also have creatinine clearance (based on a 24-hour urine collection) ≤ 60 mL/min
• No proteinuria > 1+ on dipstick analysis; in the case of > 1+ dipstick proteinuria, a 24-hour urine collection for protein must be < 500 mg/24 hours
• Urinary protein/creatinine ratio < 1
• No glomerulonephritis

Cardiovascular:

• No coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina, symptomatic congestive heart failure, severe uncontrolled hypertension, hemorrhagic or thrombotic stroke or any other CNS bleeding within the preceding 12 months
• LVEF normal by echocardiogram or MUGA within the past 12 months if there was prior exposure to anthracyclines or radiotherapy encompassing the heart

Immunologic:

• Not known to have human immunodeficiency virus (HIV), active hepatitis virus C (HVC), or active hepatitis virus B (HVB)

Other:

• Negative pregnancy test within 7 days prior to enrollment
• Not pregnant or breast feeding
• Fertile patients must agree to use effective contraception or commit to abstinence during the study period, or be surgically sterile
• No serious nonhealing wound, ulcer, or bone fracture
• Have the ability to understand and sign an informed consent document
• Be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics
• At least 4 weeks since prior biological or immunotherapy and recovered

Chemotherapy:

• See Disease Characteristics
• At least 4 weeks since prior chemotherapy and recovered
• At least 6 weeks for mitomycin C and nitrosoureas prior to study entry and recovered

Radiotherapy:

• At least 4 weeks since prior radiotherapy to a visceral organ and recovered

Surgery:

• At least 4 weeks since prior major or laparoscopic surgery and recovered
• At least 1 week since prior minor surgery

Other:

• No other concurrent anticancer therapy
• Not concurrently enrolled in another therapeutic clinical trial involving ongoing therapy
• No concurrent full dose, therapeutic anti-coagulation with warfarin or related oral anti-coagulants or unfractionated or low molecular weight heparins; low dose warfarin for catheter prophylaxis or acetylsalicylic acid ≤ 325 mg/day is acceptable

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Adnexus, A Bristol-Myers Squibb R&D Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Adnexus, A Bristol-Myers Squibb R&D Company

Locations

Indiana University Cancer Center

Indianapolis, Indiana, United States

South Texas Accelerated Research Therapeutics

San Antonio, Texas, United States

Institute for Drug Development

San Antonio, Texas, United States

Countries

United States

References

Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res. 2011 Jan 15;17(2):363-71. doi: 10.1158/1078-0432.CCR-10-1411. Epub 2011 Jan 11.

Reference Type: DERIVED

PMID: 21224368 (View on PubMed)

Other Identifiers

CT-322.001

Identifier Type: -

Identifier Source: org_study_id